Novartis has withdrawn its EU application for radioligand therapy Pluvicto’s expansion into earlier prostate cancer treatment, despite US and UK approval for the same indication.
The Swiss drugmaker failed to gain favor with the European …
After downplaying persistent rumours for months, Sun Pharma has broken cover with an $11.75 billion takeover agreement for Organon.
Indian drug giant Sun Pharma has lined up an $11.75 billion acquisition of Organon, a women’s health and biosimilar maker spun out of Merck in
After a lull in mid-2025, investment in UK biotechs appears to be picking up, according to data from the UK trade group the BioIndustry Association.
Welcome back to another edition of Endpoints Weekly! We’re doing a little bit of celebrating here at Endpoints, as we took home three Neal Awards,
The FDA dropped a surprise Friday announcement that three more National Priority Vouchers would be given to a trio of psychedelics companies.
Novartis has withdrawn its EU application for radioligand therapy Pluvicto’s expansion into earlier prostate cancer treatment, despite US and UK approval for the same indication.
The Swiss drugmaker failed to gain favor with the European …